Spain· ES:11737001
EVIPLERA 200 mg/25 mg/245 mg COMPRIMIDOS RECUBIERTOS CON PELICULA
A medicinal product containing emtricitabina + rilpivirina + tenofovir, registered in Spain by Gilead Sciences Ireland Unlimited Company.
Checked against AEMPS CIMA (Spain) on
Informational only — not a medical device.
The record
At a glance
AEMPS CIMA (Spain)- Active substance
- emtricitabina + rilpivirina + tenofovir
- Manufacturer
- Gilead Sciences Ireland Unlimited Company
- Country
- Spain (ES)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- AEMPS CIMA (Spain)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of AEMPS CIMA (Spain). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/f9e4c356-098a-4203-ae0a-bf7ec295fb19 GET /v1/drugs/f9e4c356-098a-4203-ae0a-bf7ec295fb19?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"cpresc": "Diagnóstico Hospitalario",
"estado": "{\"aut\":1327532400000}",
"nregistro": "11737001",
"substance": "emtricitabina + rilpivirina + tenofovir"
}See everything about emtricitabina + rilpivirina + tenofovir.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.